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Background: Gene mutation is an important mechanism of myeloid leukemogenesis. However, the number and
combination of gene mutated in myeloid malignancies is still a matter of investigation.
Methods: We searched for mutations in the ASXL1, CBL, FLT3, IDH1, IDH2, JAK2, KRAS, NPM1, NRAS, RUNX1, TET2 and
WT1 genes in 65 myelodysplastic syndromes (MDSs) and 64 acute myeloid leukemias (AMLs) without balanced
translocation or complex karyotype.
Results: Mutations in ASXL1 and CBL were frequent in refractory anemia with excess of blasts. Mutations in TET2
occurred with similar frequency in MDSs and AMLs and associated equally with either ASXL1 or NPM1 mutations.
Mutations of RUNX1 were mutually exclusive with TET2 and combined with ASXL1 but not with NPM1. Mutations in
FLT3 (mutation and internal tandem duplication), IDH1, IDH2, NPM1 and WT1 occurred primarily in AMLs.
Conclusion: Only 14% MDSs but half AMLs had at least two mutations in the genes studied. Based on the
observed combinations and exclusions we classified the 12 genes into four classes and propose a highly
speculative model that at least a mutation in one of each class is necessary for developing AML with simple or
normal karyotype.
Background
Myeloid leukemogenesis is a complex process that
transforms a regulated hematopoietic stem or progenitor
cell into a proliferative cell unable to differentiate. Sev-
eral genetic alterations such as translocations, gene
mutations and deletions play a role in this process.
Balanced translocations generating gene fusion play a
major leukemogenic role in some classes of leukemias.
However, they are rare in myelodysplastic syndromes
(MDSs) and the majority of adult acute myeloid leuke-
mias (AMLs) have a normal karyotype (NK-AMLs).
MDSs are a heterogeneous group of clonal diseases
characterized by bone marrow dysplasia, various degrees
of cytopenia and a risk of progression to AML [1]. The
alterations that lead to these pre-leukemic disorders are
poorly defined [2]. Several genes have been identified
recently as mutated in MDSs and AMLs, including
ASXL1, located in chromosome arm 20q, CBL, located
in 11q, and TET2, located in 4q [3-11]. These mutations
are associated with biological and prognostic features
[9,11].
Similarly, gene mutations are likely to play a role in
the development of NK-AMLs. Indeed, the identification
of mutations in several genes such as NPM1 and FLT3
has revealed prognosis subgroups and modified the clin-
ical management of these leukemias [12,13]. A recent
whole-genome sequencing study of an AML case has
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isocitrate dehydrogenase [14]. AMLs occur de novo or
after a chronic phase (hereafter called primary and sec-
ondary, respectively). Such chronic phase can be an
MDS. We have recently shown that mutations in
ASXL1,i nc o n t r a s tt oNPM1 mutations, are found in
MDSs and in secondary AMLs [15].
Mutation data are in line with the multi-hit model
proposed by Gilliland suggesting that many gene muta-
tions play a role in leukemogenesis [16]. Now that more
and more gene mutations are reported it is important to
determine when they occur in the various types of
malignant hematopoietic diseases and how they combine
in the development of leukemia. To begin to answer
these questions we searched for mutations in twelve




All patients signed an informed consent and the study
was approved by the institutional review board (“Com-
mission d’Orientation Scientifique”) of Institut Paoli-
Calmettes.
The 129 samples were selected on the absence of
known balanced translocation, and in the absence of
complex karyotype for the AML series (as defined by
more than three alterations). They included 65 cases of
MDS (Additional file 1Table S1), comprising, according
to the WHO criteria [17], 5 refractory anemia (RA), 13
refractory anemia with ring sideroblasts (RARS) (includ-
ing one with myelofibrosis), 7 refractory cytopenia with
multilineage dysplasia (RCMD), 16 refractory anemia
with excess of blasts type 1 (RAEB1), 19 refractory ane-
m i aw i t he x c e s so fb l a s t st y p e2( R A E B 2 )a n d5M D S -
unclassified (MDS-U) cases. Six cases were secondary to
hematopoietic or non-hematopoietic diseases (na in
IPSS column, Additional file 2Table S1). The majority
of MDS samples were collected at the time of diagnosis;
some were in therapeutic abstention of a known MDS
and some were under symptomatic treatment. Seventeen
cases were IPPS low risk (0), 23 were int-1 (0.5-1), 12
were int-2 (1.5-2) and 7 were high risk (≥2.5).
We studied 64 AMLs (Additional file 2Table S2)i n c l u d -
ing 46 primary cases and 18 transformations of a previous
myeloid disease (the same cohort of 64 AML patients,
listed in Additional file 2Table S2, had been analyzed for
mutations in the NPM1, FLT3, CEBPA, NRAS, KRAS,
JAK2,a n dASXL1 genes and the results already reported
in ref. 15). The panel comprised 47 cases of NK-AML and
17 cases with either trisomy 8 (n = 14), 9q deletion (HD-
0632), trisomy 11 (HD-0304) or 20q deletion (HD-0381)
as a sole karyotypic abnormality.
Array-comparative genomic hybridization (aCGH) had
been performed on almost all samples and had allowed
the detection of deletions and breaks [9,10,15,18,19].
DNA sequencing
DNA sequencing of exon-coding sequences of ASXL1,
CBL, FLT3, IDH1, IDH2, JAK2, KRAS, NPM1, NRAS,
RUNX1, TET2 and WT1 was done as follows. PCR ampli-
fications of bone marrow cell DNA were done in a total
volume of 25 μl PCR mix containing at least 5 ng tem-
plate DNA, Taq buffer, 200 μmol of each deoxynucleo-
tide triphosphate, 20 pmol of each primer and 1 unit of
Hot Star Taq (Qiagen). PCR amplification conditions
were as follows: 95°C 10 min; 95°C 30 sec, 55°C 30 sec,
72°C 30 sec to 1 min depending on PCR product length
for 35 cycles; 72°C 10 min. PCR products were purified
using Millipore plate MSNU030. One microliter of the
purified PCR products was used for sequencing using the
Big Dye terminator v1.1 kit (Applied Biosystems) includ-
ing the forward or reverse primer. After G50 purification,
sequences were loaded on an ABI 3130XL automat
(Applied Biosystems). The sequence data files were ana-
lyzed using both SeqScape and Phred/Phrap/Consed soft-
wares and all mutations were confirmed on an
independent PCR product. The exons studied were as
follows: ASXL1 exon 12, CBL exons 8 and 9, FLT3 exons
14, 15 and 20, IDH exon 4, JAK2 exon 14, RAS exons 1
and 2, NPM1 exon 12, RUNX1 exons 1 to 8, TET2 exons
3t o1 1 ,WT1 exons 7 and 9. The primers for sequencing
are listed in [Additional file 3].
Results
Mutations in MDSs
We had previously shown that ASXL1 frameshift and
nonsense mutations occurred in exon 12 [10]. ASXL1
exon 12 frameshift mutations (10 times the same p.
Gly646Trpfsx12) were observed in 12 out of the 65
MDS cases (18.5%) including 1 out of 5 RA (20%), 2 out
o f1 6R A E B 1( 1 2 . 5 % )a n d9o u to f1 9R A E B 2( 4 7 . 4 % )
(Additional file 1Table S1). We found 12 cases with
TET2 mutation (18.5%) and 4 with RUNX1 mutation
(6.2%). One patient (HD-0311) had two TET2 muta-
tions. TET2 mutations were frequent in RAEB1 (7/16,
43.8%). Mutations in RUNX1 and TET2 were mutually
exclusive but both could associate with ASXL1 muta-
tions: two cases showed both an ASXL1 and a TET2
mutation and three cases both an ASXL1 and a RUNX1
mutation. One case of ASXL1 deletion (HD-0190) and
o n ec a s eo fTET2 deletion (HD-0145) have been
reported [9,10]. One case (HD-0232) had a break in
RUNX1 detected by aCGH (not shown).
We did not find any FLT3, NPM1 or WT1 mutation.
One MDS-U had a JAK2 mutation and one RCMD case
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in CBL. In one of these the mutation was homozygous.
One subtitution occurred in the case with trisomy 11
(HD-0264), and showed a 2/3 ratio with the wild-type
residue, suggesting that the mutated allele was dupli-
cated (Figure 1a). This is in agreement with a potential
gain-of-function of the mutated CBL [20]. We found 5
IDH mutations in the 65 cases (7.7%), including 2 muta-
tions in IDH1 and 3 in IDH2.
Mutations in AMLs
We found heterozygous nonsense or frameshift muta-
tions of ASXL1 in 11 out of the 64 cases and one case
(HD-0381) was known to have a deletion (Additional
file 2 Table S2) [15]. As previously shown [15]NPM1
mutations were found in 28 cases, mostly primary cases.
We found 9 TET2 mutations in 9 cases, and 10 RUNX1
mutations in 9 cases (HD-0790 had two RUNX1 muta-
tions). In addition, HD-0198 had a break in RUNX1
[19]. These alterations were found in both primary and
secondary AMLs. Mutations in RUNX1 and TET2,
RUNX1 and NPM1,a n dASXL1 and NPM1 were
mutually exclusive, respectively. TET2 mutations could
associate with either mutated NPM1 or ASXL1.
Nineteen cases (mostly primary) had FLT3 internal
tandem duplication or point mutation. Three cases had
a RAS mutation and one a JAK2 V617F mutation. The
only CBL mutation was found in the case with a trisomy
11 (HD-0304, the corresponding transformed state of
HD-0264 MDS). Three primary cases (6.5%) showed a
WT1 mutation. Three cases were mutated in IDH1.
Four cases showed the Arg172Lys mutation in IDH2.
We also found 11 cases (17%) with the Arg140Gln sub-
stitution in IDH2 (Figure 1b).
Paired cases
For two patients both the chronic (HD-0173, HD-0264)
and acute (HD-0790, HD-0304) phases of the disease
were available (in bold in Tables). RARS HD-0173 had a
mutated RUNX1 allele. The corresponding AML (HD-
0790) had two RUNX1 mutations. RAEB2 HD-0264 had
am u t a t i o ni nASXL1, CBL and TET2 genes. In the cor-
responding AML we did not identify any additional
mutation in the studied genes.
Summary of results
Additional file 4Table S3 shows a summary of the
results on mutated (cases with two mutations are
counted as one) and deleted/broken cases. Mutations of
ASXL1 were frequent in MDSs and secondary AMLs.
Mutations of TET2 occurred with a similar frequency in
MDSs and AMLs. ASXL1 and CBL mutations were asso-
ciated with chronic phase,m a i n l yR A E B 2 .O v e r a l l ,
advanced stage MDSs had more mutations. NPM1,
Figure 1 Examples of mutations in leukemia target genes.a .s e q u e n c eo fCBL demonstrating c.1096G>A base substitution in the forward
sequence at the position indicated by an arrow in HD-0264 patient with trisomy 11. The mutation leads to Glu366Lys change in the protein
(not tolerated, SIFT). Sequence numbering is according to Genbank accessions numbers NM_005188 and NP_005179. The same sequence from
another patient without mutation is shown below for comparison. b. Novel IDH2 mutation in MDS and AML patients. Sequence of IDH2,
demonstrating c.419G>A base substitution in the reverse sequence at the position indicated by an arrow in blood cells of patient HD-0104 and
its absence in the patient’s buccal smear. The mutation leads to Arg140Gln (R140Q) change in the protein (not tolerated, SIFT). Sequence
numbering is according to Genbank accessions numbers NM_002168.2 and NP_002159.2.
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AMLs. Mutations of IDH1/2 were rare in chronic phase.
Not surprisingly, the number of mutated genes per case
was lower in MDSs than in AMLs: only 14% MDSs but
more than half AMLs had at least two gene mutations.
Discussion
We searched for mutations in a series of selected genes.
Mutations in some of these genes, such as ASXL1, CBL,
IDH and TET2, have been identified only recently in
myeloid diseases and have never been surveyed together
to date. A number of issues need be discussed.
The frequencies of mutations we observed are close to
what has been reported individually for each gene so
far. This is true for example for IDH1, NPM1, TET2
and WT1 [1,3-9,14,21,22]. In MDS we found slightly
more mutations of CBL than previously reported [11].
The IDH2 Arg140Gln was frequent in AMLs, rare in
MDSs. The mutation was not present in the buccal
smear DNA of a patient with AML (HD-0104), showing
it was acquired. The Arg140Gln mutation in IDH2 has
been reported in recent studies of myeloid diseases
[23,24]. A recent study has described ASXL1 as the
most frequently mutated gene in advanced MDSs [25],
which we confirmed here.
A repertoire of mutations
Based on the known functions of the proteins, on a pre-
vious model and classification [16], on where the muta-
tions were present (MDSs and/or secondary AMLs and/
or primary AMLs) and on how they combined (mutual
exclusion or association), we tentatively grouped the
genes in four classes. The first class includes RUNX1
and TET2. Mutations in these genes may cause clonal
dominance of hematopoietic stem cells [3]. ASXL1 and
NPM1 would constitute class II. Mutations in these
genes may promote a pathway leading towards either
primary or secondary AML [15]. Genes associated with
signaling pathways and proliferation [16] (CBL, FLT3,
JAK2, RAS) define class III. JAK2 mutation plays little
role in MDSs and NK-AMLs. We have shown that
FLT3 signaling is regulated by CBL [26]. However, the
two alterations may not be equivalent; if in our study
mutations in these genes were mutually exclusive and
w e r eb o t hm o r ef r e q u e n ti nA M L st h a ni nM D S s ,CBL
but not FLT3 mutations were frequent in RAEB2 cases.
This is in agreement with recent studies that showed
alterations of CBL in chronic myeloid diseases [11,27].
Finally, for three reasons we grouped IDH1, IDH2,a n d
WT1 i nap u t a t i v ec l a s sI V .F i r s t ,IDH and WT1 muta-
tions were exclusive but could co-occur with mutations
in genes from other classes. Second, they occurred pri-
marily in AMLs and were rare in MDSs. Third, muta-
tions of these genes could be associated with
modifications of the HIF1 and oxygen-sensing pathways
[28,29]. Class IV mutations are rather associated with
acute phase.
The existence of many cases with few or no mutations
in the selected genes, especially in some classes of
MDSs such as MDS-U, RA, RARS and RCMD but also
in primary AMLs (half of the cases with no or one
mutation), suggests that other genes remain to be stu-
died or discovered. Indeed, our study did not include
several target genes, such as CBFB [30], CDKN1A/B,
CEBPA, ETV6, KIT, NF1, NFIA [31], P53, RB1 and UTX
[32]; it did not include either a search for the recently
discovered mutations of the EZH2 gene [33,34]. More-
over, our aCGH analyses of the same series showed that
some cases without mutation in the studied genes do
have deletions of other cancer genes (for example
CDKN1B, ETV6 and UTX [32] are deleted in HD-0205)
[9,10,15]. Thus, the repertoire of altered genes in both
MDSs and AMLs is likely to include many genes and it
is probable that whole-genome sequencing studies will
confirm this. Because of this, and although no case had
four mutations, we propose that AML develops follow-
ing - at least - four cooperating mutations, one from
each class (Figure 2). This is highly speculative however;
the identification of new target genes and the study of
others will lead to a more precise picture. Also, because
we did not study AMLs with balanced translocation or
complex karyotype this model is proposed only for
AML with simple or normal karyotype.
Random or ordered accumulation?
An important question is whether the mutations occur
in a necessary order or randomly until differentiation of
the malignant hematopoietic clone is completely
blocked. RARS HD-0173 (one RUNX1 mutation) and
AML HD-0790 (two RUNX1 mutations) are instructive
samples from the same patient. It is tempting to inter-
pret this observation as a bi-allelic inactivation of the
RUNX1 gene. RUNX1 mutations are frequent in chronic
myelomonocytic leukemia [19] but rare in myeloproli-
ferative neoplasms except at the acute phase [35]. In our
series, mutations in TET2 were equally frequent in
MDSs and AMLs. Taken together this suggests that
inactivation of class I tumor suppressors (RUNX1,
TET2) can intervene at any stage, i.e. early or at pro-
gression. In studies of AMLs secondary to myeloproli-
ferative neoplasms (MPN) mutations of TET2 have
indeed been shown to occur early or late [30,36]. A
recent study showed that ASXL1 mutations were present
at the chronic stage and, in agreement with our findings,
that ASXL1, JAK2 and TET2 have non overlapping con-
tributions to myeloid transformation [36]. The order of
occurrence of ASXL1, TET2 and RUNX1 mutations may
vary in different diseases (MPNs and MDSs) and in
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was much too low in our series to draw any firm con-
clusion. The study of more paired cases is necessary to
definitely clear this issue. In contrast, some mutations
such as IDH1 and IDH2 amino acid changes were
detected at the AML rather than the MDS stage. Muta-
tions in proliferation genes - except in CBL - were rare
in MDS. Taken together this suggests that mutations in
classes III and IV may occur late in leukemogenesis.
Myeloid malignancies and cancer genes
The study of myeloid malignancies may modify the clas-
sical view of cancer gene inactivation. IDH1 mutations
do not result in a loss but in a change in activity [37].
This is in agreement with the fact that, in contrast to
ASXL1, RUNX1 and TET2, we never observed break or
deletion at IDH loci by aCGH analysis. WT1 is mutated
but also overexpressed in AMLs. Mutations in CBL are
associated with a gain-of-function [20]. NPM1 overex-
pression leads to increased cell growth [38]. We have
not so far found two mutations (or mutation and dele-
tion) in ASXL1 i nt h es a m es a m p l e .I ti sp o s s i b l et h a t
ASXL1 mutations are also associated with a gain-of-
function [39]. Only RUNX1 and TET2 may be inacti-
vated in the two-hit fashion that corresponds to “classi-
cal” tumor suppressors.
Impact of mutations on prognosis
Due to relatively small numbers our purpose was not to
address prognosis issues. Besides, it may be illusory to
study prognostic impact of tumor suppressors in the
absence of knowledge of yet unknown genes that may
serve the same function. However, some features could
be briefly noted. In contrast to TET2 mutations, which
were relatively evenly distributed among IPSS classes,
ASXL1, CBL and IDH mutations were associated with
more aggressive MDSs. Lower risk MDSs had fewer
mutations of these genes than higher risk MDSs. Half of
the 12 MDS with int-2 IPSS showed ASXL1 mutations,
and reciprocally half of the ASXL1 mutations were in
int-2 cases. Four CBL mutations were found in int-2
cases. The 7 MDSs with high IPSS had an abnormal
karyotype but few mutations (ASXL1 and RUNX1 in
HD-0377, CBL in HD-0193); this is not surprising since
karyotype status has an important weight on IPSS as
one of its components. A long follow-up on disease evo-
lution should tell if and how the mutational status
impacts on MDS progression to AML and should be
used to fine-tune IPSS.
Conclusion
We have reported here the first comprehensive study

























Figure 2 Hypothetical model summarizing frequent gene mutations in the development of two types of acute myeloid leukemia
(AML). A hematopoietic stem cell (HSC) or a progenitor cell acquires a series of mutations beginning in class I genes (green). Different
additional events (yellow, red and blue) induce clonal expansion and differentiation block and lead either towards secondary AML (sAML) via a
patent preleukemic phase or AML without patent preleukemic phase. The order of events may vary.
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Page 5 of 7and AMLs. We have proposed a speculative model of
cooperative leukemogenesis for AML with simple or
normal karyotype, which needs to be confirmed by the
study of more cases and completed by the discovery of
more genes. As this it represents a step towards the
necessary determination of the complete mutational
status of myeloid malignant diseases.
Additional material
Additional file 1: Table S1 Mutations of candidate genes in a series
of myelodysplastic syndromes.
Additional file 2: Table S2 Mutations of candidate genes in a series
of AMLs.
Additional file 3: Oligonucleotide primers used for sequencing the
coding regions of the selected genes.
Additional file 4: Table S3 Summary of results.
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